Nuo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AURX research report →
About the company
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market.
- CEO
- David E. Jorden
- IPO
- 2017
- Employees
- 9
- HQ
- Houston, TX, US
Price Chart
- Market Cap
- $48.89M
- P/E
- -20.45
- P/S
- 11.83
- P/B
- -35.24
- EV/EBITDA
- -24.26
- Div Yield
- 0.00%
- Gross Margin
- 65.46%
- Op Margin
- -53.69%
- Net Margin
- -57.72%
- ROE
- 266.09%
- ROIC
- -338.42%
- Revenue
- $3.31M · 142.72%
- Net Income
- $-2,512,216 · -8.11%
- EPS
- $-0.05 · -3.71%
- Op Income
- $-2,516,649
- FCF YoY
- 52.24%
- 52W High
- $3.23
- 52W Low
- $0.84
- 50D MA
- $1.10
- 200D MA
- $1.70
- Beta
- -104.09
- Avg Volume
- 3.03K
Get TickerSpark's AI analysis on AURX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | CLAUSEN PETER | other | 65,000 |
| Jun 30, 26 | JORDEN DAVID EMERSON | other | 162,500 |
| Jun 30, 26 | JORDEN DAVID EMERSON | other | 160,892 |
| Jun 29, 26 | JORDEN DAVID EMERSON | other | 125,000 |
| Jun 30, 26 | JORDEN DAVID EMERSON | other | 162,500 |
| Jun 30, 26 | Pittman Scott M. | other | 40,000 |
| Jun 30, 26 | Pittman Scott M. | other | 39,604 |
| Jun 29, 26 | Pittman Scott M. | other | 30,000 |
| Jun 30, 26 | Pittman Scott M. | other | 40,000 |
| Jun 30, 26 | WINZER C ERIC | other | 40,000 |
Our AURX coverage
Recent articles, reports, and earnings notes.
No research on AURX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AURX report →Similar companies
Peers in the same neighborhood.